Enzalutamide for patients with metastatic castration-resistant prostate cancer

OBJECTIVE: To review and evaluate current literature on the US Food and Drug Administration (FDA)-approved drug enzalutamide (XTANDI(®)) in metastatic castration-resistant prostate cancer. DATA SOURCES: Literature search was done through PubMed using the terms enzalutamide, MDV3100, abiraterone, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramadan, Wijdan H, Kabbara, Wissam K, Al Basiouni Al Masri, Hiba S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758/
https://www.ncbi.nlm.nih.gov/pubmed/25945058
http://dx.doi.org/10.2147/OTT.S80488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407758/
https://www.ncbi.nlm.nih.gov/pubmed/25945058
http://dx.doi.org/10.2147/OTT.S80488

Ejemplares similares